FDA Delivers Complete Response Letter for Retifanlimab for SCC Subgroup

Newly-Approved Belumosudil Yields High Overall Response Rate in Patients with Chronic Graft-Versus-Host-Disease

Antibiotic Overuse During COVID-19 Pandemic Exacerbates Need for Firmer Prescription Policies, Expert Says